Research Article
Volume 4 Issue 7 - 2020
Dapagliflozin Therapy in Adult Patients with Type 2 Diabetes: Hong Kong Data from the Association of British Clinical Diabetologists (ABCD) Nationwide Dapagliflozin Audit
MW Tsang1,4*, WB Chan2, LM Fung3 and YW Kam4
1UMP Healthcare Holdings Limited, Central, Hong Kong
2Qualigenics Medical Limited, Mongkok, Kowloon, Hong Kong
3Hong Kong Endocrine and Diabetes Centre, Jordan, Kowloon, Hong Kong
4United Christian Hospital, Kwun Tong, Kowloon, Hong Kong
*Corresponding Author: MW Tsang, UMP Healthcare Holdings Limited, Central, Hong Kong.
Received: May 27, 2020; Published: June 30, 2020




Abstract

Introduction: In this ABCD dapagliflozin audit subset, data of adult patients with type 2 diabetes from four Hong Kong local clinics initiating dapagliflozin treatment from February 2015 to January 2017 were routinely collected. Descriptive analysis was performed and expressed as frequency (%) and mean ± SD. Changes in HbA1c, body weight and other cardiometabolic parameters at Week 24 and 52 were calculated. Information on concurrent medications and adverse events was also documented.

Summary of the Results: Of all 167 patients, mean change of HbA1c from baseline (8.0 ± 1.3%) was the same at Week 24 (n = 105) and Week 52 (n = 53) at -0.8% (95% CI -1.1, -0.5). Mean change of body weight from baseline (80.9 ± 17.4 kg) was -4.0 kg (95% CI -8.3, 0.3) and -5.2 kg (95% CI -10.8, 0.4) at Week 24 and Week 52 respectively. Patients with higher baseline HbA1c (≥ 8.5%) and younger patients (< 60 years old) showed greater reduction in HbA1c compared with those with lower baseline HbA1c (< 8.5%) and older patients (≥ 60 years old) respectively at Week 52. Patients with baseline triple (or more) therapy showed a clinically meaningful reduction in HbA1c from baseline: -1.0% (95% CI -1.3, -0.7) at Week 52 (n = 42). Dapagliflozin treatment related adverse events were considered as uncommon, with genital infection being the most frequent treatment-emergent event (8%).

Conclusion: Dapagliflozin as an add-on therapy reduced HbA1c and body weight by clinically significant amounts in real-world patients with type 2 diabetes. It is effective in both young patients and those with advanced stage diabetes due to the insulin independent effect, and may allow the delay in insulin usage.

Keywords: Sodium-Glucose Co-Transporter-2 (SGLT2); Type 2 Diabetes; Association of British Clinical Diabetologists (ABCD); Dapagliflozin

References

  1. Forxiga Summary of Product Characteristics (2012).
  2. Cefalu WT and Riddle MC. “SGLT2 inhibitors: the latest “new kids on the block”. Diabetes Care 38 (2015): 352-354.
  3. Fioretto P., et al. “Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus”. Cardiovascular Diabetology 14 (2015): 142.
  4. Ferrannini E., et al. “Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise”. Diabetes Care 33 (2010): 2217-2224.
  5. Bailey CJ., et al. “Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial”. Lancet 375 (2010): 2223-2233.
  6. Bailey CJ., et al. “Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial”. BMC Medicine 11 (2013): 43.
  7. Nauck MA., et al. “Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin”. Diabetes Care 34 (2011): 2015-2022.
  8. Strojek K., et al. “Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial”. Diabetes, Obesity and Metabolism 13 (2011): 928-938.
  9. Wilding JPH., et al. “Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin”. Annals of Internal Medicine 156 (2012): 405-415.
  10. Rosenstock J., et al. “Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy”. Diabetes Care 35 (2012): 1473-1478.
  11. Jabbour SA., et al. “Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study”. Diabetes Care 37 (2014): 740-750.
  12. Hinnen D. “Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes”. Therapeutic Advances in Endocrinology and Metabolism 3 (2015): 92-102.
  13. Saeed MA and Narendran P. “Dapagliflozin for the treatment of type 2 diabetes: a review of the literature”. Drug Design, Development and Therapy 8 (2014): 2493-2505.
  14. Zou H., et al. “SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease”. Cardiovascular Diabetology 16 (2017): 65.
  15. Mikhail N. “Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes”. World Journal of Diabetes 6 (2014): 854-859.
  16. http://www.diabetologists-abcd.org.uk/n3/Dapagliflozin_Audit.htm
  17. Chao EC. “SGLT-2 inhibitors: a new mechanism for glycemic control”. Clinical Diabetes 1 (2014): 4-11.
  18. Hardy E., et al. “Efficacy increases with increasing baseline HbA1c category with dapagliflozin therapy”. Diabetes1 (2012): A23.
  19. Seufert J. “SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin”. Diabetes, Metabolic Syndrome and Obesity 8 (2015): 543-554.
  20. Mancia G., et al. “BP reduction with the sodium glucose co-transporter 2 inhibitor empagliflozin in type 2 diabetes is similar in treatment naïve as in those on one or ≥ 2 antihypertensive agents – further insights from a dedicated 24h ABPM study”. Circulation 130 (2014): A16474.
  21. Inzucchi SE., et al. “SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials”. Diabetes and Vascular Disease Research 2 (2015a): 90-100.
  22. List JF and Whaley JM. “Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans”. Kidney International 120 (2011): S20-S27.
  23. Tahrani AA and Barnett AH. “Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes”. Diabetes Therapy 2 (2010): 45-56.
  24. , et al. “Effects of dapagliflozin on cardiovascular risk factors”. Postgraduate Medical Journal 125.3 (2013): 181-189.
  25. Kalra S. “Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: a systematic review”. Cardiology and Therapy 5 (2016): 161-168.
  26. Task Force on Conceptual Model and Preventive Protocols., et al. Hong Kong Reference Framework for Diabetes Care for Adults in Primary Care Settings (2013).
  27. Cryer PE. “Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia”. Diabetes 63 (2014): 2188-2195.
  28. Klein-Schwartz W., et al. “Treatment of sulfonylurea and insulin overdose”. British Journal of Clinical Pharmacology 3 (2015): 496-504.
  29. Inzucchi SE., et al. “Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes”. Diabetes Care1 (2015b): 140-149.
  30. McGovern AP., et al. “Dapagliflozin: clinical practice compared with pre-registration trial data”. British Journal of Diabetes and Vascular Disease 14 (2014): 138-143.
  31. Chaplin S. “SGLT2 inhibitors and risk of genitourinary infections”. Prescriber 12 (2016): 26-30.
Citation: MW Tsang., et al. “Dapagliflozin Therapy in Adult Patients with Type 2 Diabetes: Hong Kong Data from the Association of British Clinical Diabetologists (ABCD) Nationwide Dapagliflozin Audit". EC Diabetes and Metabolic Research 4.7 (2020): 30-39.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


January Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the January issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before January 17, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk